Epstein Becker Green represented a private equity firm and its portfolio company in the strategic acquisition of a consumer product, cosmetic and over-the-counter (OTC) drug contract manufacturing business. Our team provided life sciences regulatory due diligence support, including an assessment of manufacturing quality compliance through EBG Advisors quality system expert resources.